Gene therapy for gastric diseases

被引：19

作者：

Fumoto, Shintaro ^{[1
]}

Nishi, Junya ^{[1
]}

Nakamura, Junzo ^{[1
]}

Nishida, Koyo ^{[1
]}

机构：

[1] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan

来源：

CURRENT GENE THERAPY | 2008年 / 8卷 / 03期

关键词：

gastric cancer; carcinoma; gastric ulcer; gene delivery; stomach;

D O I：

10.2174/156652308784746431

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Gene therapy for gastric cancer and gastric ulcer is a rationalized strategy since various genes correlate with these diseases. Since gene expressions in non-target tissues/cells cause side effects, a selective gene delivery system targeted to the stomach and/or cancer must be developed. The route of vector transfer ( direct injection, systemic, intraperitoneal, gastric serosal surface and oral administration) is an important issue which can determine efficacy and safety. Strategies for cancer gene therapy can be categorized as suicide gene therapy, growth inhibition and apoptosis induction, immunotherapy, anti-angiogenesis, and others. Combination of the target gene with other genes and/or strategies such as chemotherapy and virotherapy is promising. Candidates for treatment of gastric ulcer are vascular endothelial growth factor, angiopoietin-1, serum response factor, and cationic host defens epeptide cathelicidin. In this review, we discuss stomach and cancer-targeted gene transfer methods and summarize gene therapy trials for gastric cancer and gastric ulcer.

引用

页码：187 / 200

页数：14

共 199 条

[1] Functional diversity of helper T lymphocytes [J].

Abbas, AK ;

Murphy, KM ;

Sher, A .

NATURE, 1996, 383 (6603) :787-793

[2] Role of Raf in vascular protection from distinct apoptotic stimuli [J].

Alavi, A ;

Hood, JD ;

Frausto, R ;

Stupack, DG ;

Cheresh, DA .

SCIENCE, 2003, 301 (5629) :94-96

[3]

Atienza C, 2000, INT J MOL MED, V6, P55

[4] SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].

BAKER, SJ ;

MARKOWITZ, S ;

FEARON, ER ;

WILLSON, JKV ;

VOGELSTEIN, B .

SCIENCE, 1990, 249 (4971) :912-915

[5] Life and death decisions by E2F-1 [J].

Bell, LA ;

Ryan, KM .

CELL DEATH AND DIFFERENTIATION, 2004, 11 (02) :137-142

[6] Mitogen-activated protein kinases and nuclear factor-κB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages [J].

Bhattacharyya, A ;

Pathak, S ;

Datta, S ;

Chattopadhyay, S ;

Basu, J ;

Kundu, M .

BIOCHEMICAL JOURNAL, 2002, 368 :121-129

[7] Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS) [J].

Bhavsar, Mayank D. ;

Amiji, Mansoor M. .

JOURNAL OF CONTROLLED RELEASE, 2007, 119 (03) :339-348

[8] NF-κB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein [J].

Brandt, S ;

Kwok, T ;

Hartig, R ;

König, W ;

Backert, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (26) :9300-9305

[9] Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy [J].

Buchholz, TA ;

Davis, DW ;

McConkey, DJ ;

Symmans, WF ;

Valero, V ;

Jhingran, A ;

Tucker, SL ;

Pusztai, L ;

Cristofanilli, M ;

Esteva, FJ ;

Hortobagyi, GN ;

Sahin, AA .

CANCER JOURNAL, 2003, 9 (01) :33-41

[10] Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network - Adherens junctions and myosin light chain as targets of Rac1 and RhoA [J].

Cascone, I ;

Giraudo, E ;

Caccavari, F ;

Napione, L ;

Bertotti, E ;

Collard, JG ;

Serini, G ;

Bussolino, F .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) :50702-50713

← 1 2 3 4 5 6 7 8 9 10 →